Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination includes **olmesartan medoxomil**, an angiotensin II receptor blocker (ARB) that relaxes blood vessels; **amlodipine**, a calcium channel blocker that also relaxes blood vessels; and **hydrochlorothiazide**, a thiazide diuretic that reduces fluid in the body. The addition of **placebo** suggests a study or trial context. The combination is used to treat high blood pressure (hypertension) by lowering blood pressure and reducing the risk of cardiovascular events like strokes and heart attacks.
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)
Beyond the preview
Go deeper on olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo.